Labcorp Expands Diagnostic Network With Millennium and OPKO Health Deals

Labcorp is pursuing a major expansion of its testing portfolio through two separate transactions. The diagnostics giant recently finalized its takeover of specialty laboratory firm Millennium Health in a transaction valued at $375 million. According to a regulatory submission, the purchase structure consists of $245 million delivered up front in cash along with as much as $130 million in conditional payouts primarily tied to future top-line expansion.

The integration of Millennium Health introduces specialized urine testing services that help clinicians track patient intake of prescription pharmaceuticals and illegal substances. Labcorp said the assets will be fully absorbed into its domestic laboratory footprint, expanding toxicology testing reach across its ordering systems and patient service locations. Following the announcement of the acquisition, shares of Labcorp climbed nearly 18% to reach an all-time peak of $370.88.

Concurrently, Labcorp is working to complete another large diagnostic purchase. Under an agreement announced in October, OPKO Health decided to transfer almost the entirety of its remaining BioReference diagnostic business to Labcorp. The terms call for 722 million US dollars in upfront cash at closing, subject to adjustments, alongside up to 150 million US dollars in potential cash earnouts spread over a maximum of ten years depending on sales of the 4Kscore test. A report by HealthExec placed the total valuation of the OPKO deal at $872 million, noting that it is still subject to standard closing conditions and regulatory clearance.

These strategic acquisitions follow a profitable fiscal period for the healthcare company. In its last announced quarterly financial report, Labcorp posted adjusted earnings of $4.99 per share on $3.73 billion in revenue, reflecting a 5.8% top-line gain over the prior year. Management set full-year fiscal 2026 earnings per share guidance between 18.100 and 18.550, while analysts tracked by MarketBeat anticipated full-year earnings of about $18.32 per share.

Market analysts maintain a Moderate Buy consensus stance on Labcorp shares, based on eleven brokerage ratings compiled by MarketBeat, with an average price target of $337.73. The firm also declared a quarterly dividend of $0.72 per share, scheduled for distribution on Friday, December 11th to shareholders of record as of Tuesday, November 24th.